Couple accuses major Australian IVF provider of sperm-donor mix-up after birth of child

A Queensland couple says they were given a child fathered by a different sperm donor than the one they selected at an assisted‑reproduction clinic in 2013, and they allege the clinic worked to conceal the error for more than a decade.

The couple say they underwent treatment with the Queensland Fertility Group (QFG), which is owned by Australian fertility company Virtus Health, and that a laboratory mix‑up after two men donated sperm on the same day resulted in their child being fathered by an unidentified donor. The account was reported by the ABC program 7.30 and media outlets in Australia.

According to the couple, they had requested sperm from a Caucasian donor with features similar to the woman's husband. After the child was born, the mother noticed the child's darker skin tone differed from both parents and raised the concern in an anonymous online group. The couple subsequently sought further information from QFG because they wanted to know whether the unidentified donor had any known health or genetic conditions.

The couple and reporting by 7.30 say the mix‑up stemmed from a failure to follow a practice known as double witnessing — a procedure in which two clinicians or technicians independently verify donor identity and labelling at critical points in handling gametes. Double witnessing is described as a standard safeguard in Australian fertility clinics. The couple allege that the error occurred at a partnered laboratory in the United States, where the double‑witnessing process was not carried out to the standard expected in Australia.

They say the clinic subsequently did not disclose the full circumstances, and that QFG sought to minimise or hide the mistake. The allegations have not been independently verified by this outlet. Virtus Health and Queensland Fertility Group did not immediately respond to requests for comment in coverage by Australian media.

The case highlights concerns that can arise when donor gametes are handled across international laboratories and when standard verification procedures are absent or inconsistent. Fertility‑treatment safeguards such as independent witnessing are intended to prevent mismatches of gametes and ensure that donor medical and genetic histories accompany recipients who need them.

Counselling and information about donor medical histories are central to many patients' treatment decisions, particularly when recipients choose a donor based on physical characteristics or family medical history. The couple in this case told reporters they love the child and were not seeking to challenge parentage; rather, they wanted to know whether there were any medical risks tied to the unidentified donor.

The matter has prompted renewed scrutiny of clinic recordkeeping and cross‑border laboratory arrangements in the fertility sector. Regulators and professional bodies in Australia set standards for laboratory practice and the handling of donor material; it is unclear from available reports whether the alleged failures in this case were investigated by relevant authorities at the time of the treatment or in subsequent years.

This account joins other cases internationally in which IVF patients have raised concerns about misidentification, documentation errors or mismatches in donor material. In response to such incidents, some jurisdictions have tightened verification procedures, enhanced recordkeeping requirements and increased transparency measures for patients.

The couple's experience, as reported by the ABC and subsequent Australian media coverage, underscores the continuing importance of clear protocols and patient access to donor health information in assisted‑reproduction services. Further developments may depend on any inquiries by regulators or responses from QFG and Virtus Health to the allegations.